Patients enrolled in HIV care in mozambique: Baseline characteristics and follow-up outcomes

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages

  Lahuerta, Maria ^a   Lima, Josue ^a   Elul, Batya ^a   Okamura, Mie ^a   Alvim, Maria Fernanda ^a   Nuwagaba Biribonwoha, Harriet ^a   Horowitz, Deborah ^a   Fernandes, Rufino ^a   Assan, Americo ^b   Abrams, Elaine J ^a   El Sadr, Wafaa M ^a   Nash, Denis ^a  

^a Mailman School of Public Health ^*  (United States)

^b MINISTRY OF HEALTH   (Mozambique)

Author keywords

antiretroviral treatment; HIV care; HIV AIDS; implementation science; Mozambique; operations research; PEPFAR; scale up

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DEATH; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFANT; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; MOZAMBIQUE; NOMOGRAM; PREGNANT WOMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; REFERENCE DATABASE; SCHOOL CHILD; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; MALE; MOZAMBIQUE; PREGNANCY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80054948427     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31822ac0a9     Document Type: Article

References (32)

1. WHO. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2010. Geneva, Switzerland: WHO; 2010.
2. Institute of Medicine. Scaling up Treatment for the Global AIDS Pandemic. Washington, DC: The National Academies Press; 2005.
3. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Framework for Operations and Implementation Research in Health and Disease Control Programs. Geneva, Switzerland: The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2008.
4. WHO. HIV Testing, Treatment and Prevention: Generic Tools for Operational Research. Geneva, Switzerland: WHO; 2009.
5. Mozambique Ministry of Health (MISAU). INSIDA, Inquérito Nacional de Prevalência, Riscos Comportamentais e Informacxão sobre o HIV e SIDA em Mocxambique (National Seroprevalence, Behavioral Risk and HIV/AIDS Information Survey. Preliminary Results. Mozambique Ministry of Health; 2010.
6. United Nations General Assembly Special Session on HIV and AIDS. Mozambique Progress Report 2008-2009. UNAIDS; March 2010.
7. CDC. Revised classification system for human immunodeficiency virus infection. MMWR Recomm Rep. 1994;43(No. RR-2):1-10.
8. Kuczmarski R, Ogden C, Guo S, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat. 2002;11:1-203.
9. Egger M, Spyche B, Sidle J, et al. Correcting mortality for loss to follow up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med. 2011;8:e1000390.
10. UNAIDS/WHO. Epidemiological Fact Sheets on HIV and AIDS, 2008 Update. World Health Organization; 2008.
11. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach. World Health Organization; 2010.
12. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(suppl 1):1-15.
13. Arrive E, Kyabayinze DJ, Marquis B, et al. Cohort profile: the paediatric antiretroviral treatment programmes in lower-income countries (KIDS-ART-LINC) collaboration. Int J Epidemiol. 2008; 37:474-480. (Pubitemid 351803999)
14. Davies MA, Keiser O, Technau K, et al. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99: 730-737.
15. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-567. (Pubitemid 351931216)
16. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300: 506-507.
17. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIVinfected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7:234-244.
18. Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010;24:2717-2725.
19. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIVinfected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7:234-244.
20. Nash D,Wu Y, Elul B, et al. Program and contextual-level determinants of low median CD4+ cell count in cohorts of persons initiating ART in 8 sub-Saharan African countries. AIDS. 2011;25. E-pub ahead of print (doi: 10.1097/QAD.1090b1013e32834811b32834812).
21. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resourcelimited settings: systematic review and meta-analysis. PLoS One. 2009; 4:e5790.
22. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
23. Bekker LG, Myer L, Orrell C, et al. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96:315-320.
24. Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52: 282-289.
25. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 ,200 cells/microL) with HIV infection. HIV Med. 2004;5:93-98. (Pubitemid 38404662)
26. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17; quiz CE11-CE14.
27. Bunnell R, Mermin J, De Cock KM. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA. 2006;296: 855-858. (Pubitemid 44223108)
28. Cohen MS, Hellmann N, Levy JA, et al. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest. 2008; 118:1244-1254. (Pubitemid 351500417)
29. WHO. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2009. Geneva, Switzerland: WHO; 2009.
30. Mozambique Ministry of Health. National ART Data for Jul 2010. Maputo, Mozambique: Mozambique Ministry of Health (MISAU). Available at: http://www.misau.gov.mz/pt/hiv-sida/programa-de-tratamento-antiretroviral-tarv/ dados-tarv-nacionais. Accessed September 14, 2010.
31. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995; 142:1255-1264. (Pubitemid 26006424)
32. Nash D, Katyal M, BrinkhofMW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008;22:2291-2302.